Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

September 11th 2024

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Oral Rinse-Based Test Demonstrates Ability to Detect Recurrence of Head and Neck Cancer

September 9th 2024

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

September 4th 2024

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

September 4th 2024

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Value of PD-L1 Biomarker in NPC

August 28th 2024

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Overview of the JUPITER and POLARIS-2 Trials

August 28th 2024

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

FDA Grants Fast Track Designation to Neoadjuvant APG-157 for Head and Neck Cancer

August 23rd 2024

The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.

Current Guidelines for Managing Nasopharyngeal Carcinoma

August 21st 2024

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

August 21st 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Tumor-Killing Technology in Head and Neck Cancer

August 19th 2024

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCC

August 19th 2024

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Cannabis-Use Disorder Demonstrates a Link With Developing Head and Neck Cancer

August 14th 2024

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

Dr Leidner on the Multivalent Vaccine DPV-001 in Advanced or Metastatic HNSCC

August 8th 2024

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Dr Perez on the Efficacy and Safety of Frontline Petosemtamab Plus Pembrolizumab in HNSCC

August 8th 2024

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma

August 6th 2024

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.

UV1 Plus Pembrolizumab Fails to Yield Survival Benefit in Metastatic/Recurrent Head and Neck Cancer

August 5th 2024

UV1 plus pembrolizumab did not improve progression-free survival or overall survival in patients with metastatic or recurrent head and neck cancer.

Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCC

July 31st 2024

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

CHMP Recommends Toripalimab Plus Chemo for Metastatic Nasopharyngeal Carcinoma and Advanced ESCC

July 29th 2024

The EMA’s CHMP has recommended toripalimab plus chemotherapy for metastatic nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma.

Pembrolizumab Plus Chemo Elicits Responses in Head and Neck Squamous Cell Carcinoma

July 27th 2024

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

July 25th 2024

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.